Combination therapy with immune agonists and senescence-inducing agents delivers promise for immunotherapeutic success in pancreatic cancer

J Leukoc Biol. 2025 Feb 13;117(2):qiae234. doi: 10.1093/jleuko/qiae234.

Renee R Anderko^{1

2}, Amer H Zureikat^{1

2

3}, Tullia C Bruno^{2

4

5

6}

¹ Department of Surgery, Division of Surgical Oncology, University of Pittsburgh, 5150 Centre Avenue, Pittsburgh, PA 15232, United States.
² UPMC Hillman Cancer Center, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15213, United States.
³ Division of Surgical Oncology, University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA 15232, United States.
⁴ Tumor Microenvironment Center, UPMC Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, United States.
⁵ Cancer Immunology and Immunotherapy Program (CIIP), UPMC Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, United States.
⁶ Department of Immunology, University of Pittsburgh, 5051 Centre Avenue, Pittsburgh, PA 15213, United States.

No abstract available

Keywords: PDAC; TME remodeling; immunotherapy; nanoparticles; tertiary lymphoid structures.